Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
Sponsor: BeOne Medicines
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Official title: A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
118
Start Date
2026-06-23
Completion Date
2028-09-30
Last Updated
2026-08-10
Healthy Volunteers
No
Conditions
Interventions
BG-75202
Administered orally
Hypomethylation Agent (HMA)
Administered Intravenous (IV) or Subcutaneous (SC)
Locations (10)
Concord Repatriation General Hospital
Concord, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
Tianjin, Tianjin Municipality, China
Auckland City Hospital
Auckland, New Zealand